Benitec Biopharma Inc. (BNTC) Key Metrics
BNTC valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $282.9M
- Enterprise value
- $164.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.25
BNTC key metrics, FY2025–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsBNTC valuation Price multiples at each fiscal year-end price.
BNTC returns How much profit the business earns on the capital it uses.
BNTC per-share figures Results divided by the shares outstanding at year-end.
BNTC financial health Debt, liquidity and how easily interest is covered.
BNTC efficiency & capital use Working capital cycle and where the cash goes.
BNTC valuation history
BNTC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BNTC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BNTC price vs earnings per share
BNTC key metrics
FY2025–FY2026| FY2026 | FY2025 | |
|---|---|---|
| Valuation | ||
| Market capitalization | $622.9M | $423.6M |
| Enterprise value | $443.7M | $326.8M |
| Price / book | 3.5 | 4.4 |
| Earnings yield | −7.3% | −9.0% |
| Free cash flow yield | −2.7% | −5.6% |
| Share price at fiscal year-end | $13.38 | $11.70 |
| Per share | ||
| Revenue per share | $0.00 | $0.00 |
| Earnings per share | −$0.98 | −$1.05 |
| Operating cash flow per share | −$0.35 | −$0.65 |
| Free cash flow per share | −$0.36 | −$0.65 |
| Cash per share | $3.87 | $2.70 |
| Book value per share | $3.80 | $2.69 |
| Tangible book value per share | $3.80 | $2.69 |
| Capex per share | $0.00 | $0.00 |
| Debt per share | $0.02 | $0.02 |
| Shares outstanding | 46.6M | 36.2M |
| Change in shares outstanding | +28.6% | — |
| Returns & profitability | ||
| Return on equity (ROE) | −33.2% | −39.0% |
| Return on assets (ROA) | −32.3% | −38.1% |
| Return on tangible assets | −24.9% | −38.1% |
| Financial health | ||
| Total debt | $762,000 | $849,000 |
| Cash & short-term investments | $180.0M | $97.7M |
| Net debt | −$179.2M | −$96.9M |
| Debt / equity | 0.00 | 0.01 |
| Debt / assets | 0.00 | 0.01 |
| Current ratio | 34.00 | 54.67 |
| Quick ratio | 34.00 | 54.67 |
| Interest coverage | — | -12.7 |
| Working capital | $176.3M | $96.7M |
| Invested capital | −$2.2M | $400,000 |
| Tangible asset value | $177.0M | $97.3M |
| Net current asset value | $176.1M | $96.2M |
| Graham net-net per share | $3.75 | $2.64 |
| Capital allocation | ||
| Capex / depreciation | 0.22 | 0.05 |
| Efficiency | ||
| Days payables outstanding | 422.7 | 185.3 |
| Receivables turnover | 0.00 | 0.00 |
| Payables turnover | 0.86 | 1.97 |
| Asset turnover | 0.00 | 0.00 |
| Average receivables | $18,500 | $33,000 |
| Average payables | $557,000 | $201,000 |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from BNTC's annual financial statements (latest annual report filed September 14, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BNTC valuation and financial ratios
Benitec Biopharma earned a return on equity of −33.2% in fiscal 2026. It ended the year with $0.8 million of debt and $180.0 million in cash and short-term investments, a net cash position of $179.2 million.
See the BNTC income statement, the BNTC chart for price history, or the BNTC stock overview for the latest quote and news.
BNTC key metrics FAQ
What is Benitec Biopharma's return on equity?
Benitec Biopharma's return on equity (ROE) was −33.2% in fiscal 2026: net income of -$45.5 million on average shareholders' equity of $137.2 million.
How much debt does Benitec Biopharma have?
Benitec Biopharma had total debt of $0.8 million at the end of fiscal 2026, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Benitec Biopharma's free cash flow yield?
Benitec Biopharma generated -$16.6 million of free cash flow in fiscal 2026, a free cash flow yield of −2.7% on its market value at year-end ($622.9 million).
What is Benitec Biopharma's current ratio?
Benitec Biopharma's current ratio was 34.00 at the end of fiscal 2026: current assets were 34.00 times current liabilities.